Sign in

    MoonLake Immunotherapeutics (MLTX)

    You might also like

    Business Description

    MoonLake Immunotherapeutics (MLTX) is a clinical-stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases. The company is primarily engaged in the development of Sonelokimab (SLK), a novel tri-specific IL-17A and IL-17F inhibiting Nanobody. MLTX aims to address significant unmet needs in dermatology and rheumatology through its innovative therapeutic approach.

    1. Sonelokimab (SLK) - Develops a tri-specific IL-17A and IL-17F inhibiting Nanobody for treating inflammatory diseases such as Hidradenitis Suppurativa, Psoriatic Arthritis, and Psoriasis. SLK offers advantages like high affinity, selective binding, and enhanced tissue penetration due to its small size and albumin-binding domain.

    Key Metrics

    View all financials →

    Executive Team

    NamePositionStart DateShort Bio
    Dr. Jorge Santos da SilvaChief Executive Officer (CEO)April 2022Dr. Santos da Silva co-founded MoonLake AG and served as its CEO from July 2021 until the merger. Previously, he was a Senior Partner at McKinsey & Company (2007–2021), leading pharmaceutical and biotech practices.
    Dr. Kristian ReichChief Scientific Officer (CSO)April 2022Dr. Reich co-founded MoonLake AG and served as its CSO from May 2021 until the merger. He has over 25 years of experience in dermatology and immunology, with 300+ publications and notable awards.
    Matthias BodenstedtChief Financial Officer (CFO)April 2022Mr. Bodenstedt was CFO of MoonLake AG from July 2021 until the merger. Previously, he was a Partner at McKinsey & Company (2011–2021), advising biotech and pharmaceutical clients. He holds advanced degrees in finance.